National Quality Forum Medication Measures for Ambulatory Care

**Overview**
This data package is contains information on providing services for the Medication Measures Special Innovation Project, the purpose of which is to develop measures that can be used to support quality healthcare delivery to Medicare beneficiaries. The project currently has a portfolio of eight NQF-endorsed measures for the ambulatory care setting, NQF 0543, NQF 0545, NQF 0555, NQF 0556, NQF 1879, NQF 1880, NQF 2362, NQF 2363, NQF 2379, NQF 2467, NQF 2468.

**Description**
CMS has contracted with FMQAI (Florida's Medicare Quality Improvement Organization) to provide services for the Medication Measures Special Innovation Project, the purpose of which is to develop measures that can be used to support quality healthcare delivery to Medicare beneficiaries. The project currently has a portfolio of eight NQF-endorsed measures for the ambulatory care setting, NQF 0543, NQF 0545, NQF 0555, NQF 0556, NQF 1879, NQF 1880, NQF 2362, NQF 2363, NQF 2379, NQF 2467, NQF 2468. The key objectives of the project are to:
- Develop new and maintain previously developed medication measures with the potential for National Quality Forum (NQF) endorsement.
- Adapt/specify existing NQF-endorsed medication measures and develop new measures for implementation in CMS reporting programs, such as
- Hospital Inpatient Quality Reporting (IQR) Program
- Hospital Outpatient Quality Reporting (OQR) Program
- Physician Quality Reporting System (PQRS)
- Others as directed by CMS, such as long-term care settings and ambulatory care settings.
- Continue to develop new medication measures that address the detection and prevention of adverse medication-related patient safety events that can be used in future Quality Improvement Organization (QIO) Statements of Work and in CMS provider reporting programs; and
- Identify and specify up to five new adverse event measures (non-medication-related) that could be used in future QIO programs and CMS provider reporting programs in the hospital setting (inpatient and/or emergency department). In addition to maintenance of previously developed medication measures, the new measures to be developed under this special project support QIO patient safety initiatives by addressing topics, such as the detection and prevention of medication errors, adverse drug reactions, and other patient safety events. Under this Special Innovation Project, existing measures, as well as new measures, are being refined and specified for implementation in provider reporting programs.

**Benefits**
- This data package is used to support quality healthcare delivery to medicare beneficiaries

**License Information**
The use of John Snow Labs datasets is free for personal and research purposes. For commercial use please subscribe to the [Data Library](https://www.johnsnowlabs.com/marketplace/) on John Snow Labs website. The subscription will allow you to use all John Snow Labs datasets and data packages for commercial purposes.

**Included Datasets**
- [Adherence to ACEIs and ARBs For Diabetes Mellitus NQF 2467](https://www.johnsnowlabs.com/marketplace/adherence-to-aceis-and-arbs-for-diabetes-mellitus-nqf-2467)
- This dataset contains the information on the measure "Adherence to ACEIs and ARBs For Diabetes Mellitus NQF 2467" which is the Percentage of individuals at least 18 years of age with diabetes mellitus who had at least two prescription drug claims for oral angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and had a Proportion of Days Covered (PDC) of at least 0.8 for ACEIs/ARBs in 2013. This measure is paired with NQF 0545 and NQF 2468.
- [Adherence to Antiplatelet Therapy After Stent Implantation NQF 2379](https://www.johnsnowlabs.com/marketplace/adherence-to-antiplatelet-therapy-after-stent-implantation-nqf-2379)
- This dataset contains the information on the measure "Adherence to Antiplatelet Therapy After Stent Implantation NQF 2379"
which is the average proportion of days covered (PDC) for individuals with antiplatelet therapy during the 12 months (year 2019) following implantation of a coronary artery drug-eluting stent (DES) regardless of indication or a bare-metal stent (BMS) for acute coronary syndrome (ACS).
- [Adherence to Antipsychotic Medications for Schizophrenia NQF 1879](https://www.johnsnowlabs.com/marketplace/adherence-to-antipsychotic-medications-for-schizophrenia-nqf-1879)
- This dataset contains the information on the measure "Adherence to Antipsychotic Medications for Schizophrenia NQF (National Quality Forum) 1879" which is the Percentage of individuals at least 18 years of age with schizophrenia or schizoaffective disorder who had at least two prescription drug claims for antipsychotic medications and had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the measurement period (12 consecutive months of the year 2012.
- [Adherence to Mood Stabilizers For Bipolar I Disorder NQF 1880](https://www.johnsnowlabs.com/marketplace/adherence-to-mood-stabilizers-for-bipolar-i-disorder-nqf-1880)
- This file contains the information on the measure "Adherence to Mood Stabilizers For Bipolar I Disorder NQF (National Quality Forum) 1880" which is the Percentage of individuals at least 18 years of age as of the beginning of the measurement year 2013 with bipolar I disorder who had at least two prescription drug claims for mood stabilizer medications and had a Proportion of Days Covered (PDC) of at least 0.8 for mood stabilizer medications during the measurement period (12 consecutive months).
- [Adherence to Oral Diabetes Agents For Diabetes Mellitus NQF 2468](https://www.johnsnowlabs.com/marketplace/adherence-to-oral-diabetes-agents-for-diabetes-mellitus-nqf-2468)
- This dataset contains the information on the measure "Adherence to Oral Diabetes Agents For Diabetes Mellitus NQF (national Quality FOrum) 2468" which is the Percentage of individuals at least 18 years of age as of the beginning of the measurement period with diabetes mellitus who had at least two prescription drug claims for oral diabetes agents (ODAs) and had a Proportion of Days Covered (PDC) of at least 0.8 for ODAs during the measurement year 2013. It is paired with NQF 0545 and NQF 2467.
- [Adherence to Statin Therapy with Coronary Artery Disease NQF 0543](https://www.johnsnowlabs.com/marketplace/adherence-to-statin-therapy-with-coronary-artery-disease-nqf-0543)
- This dataset contains the information on the measure "Adherence to Statin Therapy with Coronary Artery Disease NQF (National Quality Forum) 0543" which is the percentage of individuals with Coronary Artery Disease (CAD) who are prescribed statin therapy that had a Proportion of Days Covered (PDC) for oral statin medications of at least 0.8 during the measurement year 2011.
- [Adherence to Statins for Individuals with Diabetes Mellitus NQF 0545](https://www.johnsnowlabs.com/marketplace/adherence-to-statins-for-individuals-with-diabetes-mellitus-nqf-0545)
- This dataset contains the information on the measure "Adherence to Statins for Individuals with Diabetes Mellitus NQF (National Quality Forum) 0545" or "NQF-0545" which addresses adherence to three types of chronic medications; statins, angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) and oral hypoglycemic agents.
- [INR For Warfarin and Interacting Anti Infective Medications NQF 0556](https://www.johnsnowlabs.com/marketplace/inr-for-warfarin-and-interacting-anti-infective-medications-nqf-0556)
- This dataset contains the information on the measure "INR For Warfarin and Interacting Anti Infective Medications NQF 0556 (National Quality Forum 0556), which is the Percentage of episodes with an International Normalized Ratio (INR) test performed three to seven days after a newly started interacting anti-infective medication for individuals receiving warfarin.
- [International Normalized Ratio INR Monitoring on Warfarin NQF 0555](https://www.johnsnowlabs.com/marketplace/international-normalized-ratio-inr-monitoring-on-warfarin-nqf-0555)
- This dataset contains the information on the measure "International Normalized Ratio INR Monitoring on Warfarin NQF 0555" which is the Percentage of individuals at least 18 years of age as of the beginning of the measurement period with at least 56 days of warfarin therapy (Warfarin Sodium in the form of tablet, given orally) who receive an International Normalized Ratio (INR) test during each 56-day interval with warfarin.

**Data Engineering Overview**
**We deliver high-quality data**
- Each dataset goes through 3 levels of quality review
- 2 Manual reviews are done by domain experts
- Then, an automated set of 60+ validations enforces every datum matches metadata & defined constraints
- Data is normalized into one unified type system
- All dates, unites, codes, currencies look the same
- All null values are normalized to the same value
- All dataset and field names are SQL and Hive compliant
- Data and Metadata
- Data is available in both CSV and Apache Parquet format, optimized for high read performance on distributed Hadoop, Spark & MPP clusters
- Metadata is provided in the open Frictionless Data standard, and its every field is normalized & validated
- Data Updates
- Data updates support replace-on-update: outdated foreign keys are deprecated, not deleted

**Our data is curated and enriched by domain experts**

Each dataset is manually curated by our team of doctors, pharmacists, public health & medical billing experts:
- Field names, descriptions, and normalized values are chosen by people who actually understand their meaning
- Healthcare & life science experts add categories, search keywords, descriptions and more to each dataset
- Both manual and automated data enrichment supported for clinical codes, providers, drugs, and geo-locations
- The data is always kept up to date – even when the source requires manual effort to get updates
- Support for data subscribers is provided directly by the domain experts who curated the data sets
- Every data source’s license is manually verified to allow for royalty-free commercial use and redistribution.

**Need Help?**
If you have questions about our products, contact us at [[e-mail]](mailto:[e-mail]).

搜集汇总

背景与挑战

背景概述

该数据集包含美国国家质量论坛认可的8种门诊药物使用质量指标，用于评估和改善医疗保险受益人的医疗服务质量，涵盖糖尿病、精神疾病和心血管疾病等多个领域的用药规范监测。数据经过严格的质量审核和标准化处理，适用于医疗质量改进和研究用途。